Geneva (TDI): World Health Organization (WHO) has granted approval to first monkeypox virus vaccine developed by Bavarian Nordic A/S for prequalification.
The MVA-BN is the first-ever mpox vaccine to be added to the WHO’s prequalification list.
WHO Director General (DG) Tedros Adhanom Ghebreyesus said that the prequalification is set to significantly increase access to the vaccine in regions experiencing urgent outbreaks, particularly in Africa.
This move is anticipated to aid in reducing transmission and controlling the spread of the disease.
He also highlighted the need to increase vaccine procurement and distribution to ensure that those most at risk can obtain it.
Mpox Vaccine
The vaccine necessitates two doses administered four weeks apart for individuals aged 18 and over.
Data shows that it is 76 percent effective after the first dose and 82 percent effective after the second dose.
The WHO has called for continued data collection to monitor the vaccine’s safety and effectiveness.
According to WHO Assistant Director-General Yukiko Nakatani, this prequalification will expedite procurement by international agencies and facilitate faster national regulatory approvals.
Read More: WHO Chief Talks to UN On Mpox Outbreak In Congo
The recent approval comes amid the ongoing mpox outbreak, which has affected over 120 countries with more than 103,000 reported cases since 2022.
In 2024 alone, Africa has seen 25,237 suspected and confirmed cases and 723 deaths across 14 countries, according to the WHO.
This highlights the urgent need for continued global efforts and resources to manage and mitigate the impact of the disease.
 has granted approval to first monkeypox virus vaccine developed by Bavarian Nordic A/S for... Read More){kind=link}